Pharmafile Logo
Pharmafocus logo
Advanced Search

NSCLC

Showing 15 posts of 129 posts found.

astrazeneca_building_white

AZ’s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer

April 19, 2018
Sales and Marketing AstraZeneca, Cancer, EGFR-TKIs, NSCLC, Tagrisso, lung cancer, pharma

AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from …

News
merckwindow_web

Keytruda success continues, beating Opdivo in lung cancer survival

April 17, 2018
Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

Not content with revealing two strong waves of data on its flagship immunotherapy Keytruda (pembrolizumab) over the past weeks, MSD …

News
msd

Keytruda scores big as a first-line monotherapy in NSCLC patients with any level of PD-L1 expression

April 10, 2018
Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

Closely following the news that Keytruda (pembrolizumab) had failed in the treatment of unresectable or metastatic melanoma as a combination …

News

BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression

February 6, 2018
Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, NSCLC, Yervoy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination …

News
pfizer-building-logo1web

Pfizer’s Xalkori sees rejection at the hands of NICE in lung cancer

January 19, 2018
Medical Communications, Sales and Marketing Cancer, NCIE, NSCLC, Pfizer, UK, Xalkori, lung cancer, pharma

UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the …

News

Boehringer’s Gilotrif approved in US for lung cancer with non-resistant EGFRs

January 16, 2018
Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, Cancer, FDA, Giltrif, NSCLC, lung cancer

Boehringer Ingelheim is celebrating the FDA’s decision to expand the indication of its lung cancer drug Gilotrif (afatinib) to include …

News
shutterstock_212432119

Moffitt scientists discover new applications for Novartis’s Zykadia

October 11, 2017
Research and Development Cancer, Moffitt, NSCLC, ceritinib, lung cancer, zykadia

Through the use of molecular screening, functional proteomics and computer-based modelling, researchers from the Moffitt Cancer Center have been working …

News
astrazeneca-sign

AstraZeneca’s Tagrisso secures Breakthrough Therapy Designation in first-line NSCLC

October 9, 2017
Sales and Marketing AstraZeneca, Cancer, NSCLC, immunotherapy, lung cancer

AstraZeneca has announced that its targeted therapy, Tagrisso (osimertinib), has been awarded Breakthrough Therapy Designation by the FDA for the …

News
astrazeneca_plaque

AstraZeneca’s Tagrisso beats standard of care in halting NSCLC

September 11, 2017
Research and Development, Sales and Marketing AstraZeneca, ESMO, NSCLC, Tagrisso, non-small cell cell cancer, pharma, pharmaceutical

AstraZeneca has revealed new data at the European Society of Medical Oncology (ESMO) on the efficacy of Tagrisso (osimertinib) in …

News
novartis_headquarters

Novartis gains first-line approval for Zykadia in lung cancer

June 29, 2017
Research and Development EMA, European Commission, NSCLC, Novartis

The European Commission has followed the EMA’s CHMP positive opinion by approving Novartis’ Zykadia for first-line treatment of patients with …

News
novartis_outside_1

Novartis lung cancer combo receives FDA approval

June 23, 2017
Medical Communications, Sales and Marketing NSCLC, Novartis

Novartis has revealed that its drug Tafinlar (dabrafenib) has received approval from the FDA for use in combination with Mekinist …

News
pfizer_finland_hq

Pfizer drug beats AZ rival in halting lung cancer

June 6, 2017
Manufacturing and Production, Research and Development NSCLC, Pfizer

New data from late-stage trials suggests that Pfizer’s dacomitinib beat out AstraZeneca’s rival treatment Iressa (gefitinib) at halting the progression …

News
novartis_outside_1

FDA approves Novartis’ Zykadia as first-line lung cancer treatment

May 30, 2017
Manufacturing and Production, Sales and Marketing FDA, NSCLC, Novartis

The FDA has announced it has approved Novartis’ Zykadia (ceritinib) as a first line treatment in the expanded indication of …

News
astrazeneca_building_white

AZ’s Tagrisso continues successes with EU approval

April 26, 2017
Research and Development, Sales and Marketing AstraZeneca, EU, European Commission, NSCLC, Tagrisso

More good news for AstraZeneca’s Tagrisso (osimertinib), as the company announces that the European Commission has granted the drug full …

News
european_commission

Novartis combo expands into lung cancer with EU approval

April 4, 2017
Manufacturing and Production, Sales and Marketing NSCLC, Novartis, Tafinlar, mekinist

Novartis has announced that its Tafinlar (dabrafenib) and Mekinist (trametinib) drug combo has been approved by the European Commission (EC) …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023